Every 8-K that Anavex Life Sciences (AVXL) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow AVXL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AVXL filings page.
ANAVEX LIFE SCIENCES CORP. (AVXL) reports a regulatory development related to its ANAVEX®2-73 (blarcamesine) program in Rett syndrome. The company is advancing a Phase 3 clinical trial in adult Rett patients in the United States and has received U.S. Food and Drug Administration agreement to hold a meeting to discuss potential inclusion of pediatric patients in this Phase 3 study. Anavex states that ANAVEX 2-73 remains a priority in its clinical development pipeline for early Alzheimer’s disease, Rett syndrome and Fragile X syndrome.
ANAVEX LIFE SCIENCES CORP. (AVXL) reports that it has regained compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of all required periodic reports with the SEC. Compliance was restored after the company filed its outstanding Form 10-Qs for the quarters ended March 31, 2026 and June 30, 2026.
Nasdaq has confirmed that Anavex now meets all Nasdaq listing standards, and the company’s common stock will continue to trade on the Nasdaq Global Select Market under the ticker AVXL.
ANAVEX LIFE SCIENCES CORP. (AVXL) reported third fiscal quarter 2026 results and a business update focused on its Alzheimer’s disease, Rett syndrome and Fragile X syndrome programs. For the quarter ended June 30, 2026, AVXL recorded net income of $7.8 million, or $0.08 per share, versus a net loss of $13.2 million, or $0.16 per share, a year earlier.
Quarterly general and administrative and research and development lines showed net recoveries due mainly to reversing $17.4 million of stock-based compensation tied to terminated employees, primarily the former CEO. Cash and cash equivalents were $118.3 million, up from $102.6 million at September 30, 2025, and the company expects this to fund operations into mid to late fiscal 2028. For the nine months ended June 30, 2026, AVXL still reported a net loss of $3.2 million and an accumulated deficit of $385.6 million.
Operationally, AVXL submitted completed Alzheimer’s clinical study data to its Alzheimer’s IND, requested an FDA meeting on adding pediatric patients to the Rett syndrome Phase 3 study, and plans an IND submission for Fragile X syndrome in September. The company also highlighted risks, including regaining Nasdaq listing compliance, delayed Form 10-Q filings, and litigation related to the former CEO’s termination.
Anavex Life Sciences Corp. reported that its Board’s Executive Committee has mailed a letter to stockholders regarding the 2026 Annual Meeting of Stockholders and launched a dedicated website, www.VoteAnavex.com, which provides information about the meeting, the proxy process, and the company’s director nominees.
The letter encourages stockholders to vote the WHITE proxy card “FOR” six director nominees standing for election at the 2026 Annual Meeting. The Annual Meeting is scheduled for September 24, 2026, and stockholders of record at the close of business on July 31, 2026 are entitled to vote. The company also highlights where to find its definitive proxy statement and related materials filed with the SEC.
Anavex Life Sciences Corp. reported that it has filed definitive proxy materials for its 2026 Annual Meeting of Stockholders, scheduled for September 24, 2026, with stockholders of record on July 31, 2026 entitled to vote. The company’s board is soliciting support for six director nominees and has mailed an open letter describing its governance and strategic priorities, including advancing oral blarcamesine (ANAVEX®2-73) in early Alzheimer’s disease, Rett syndrome, and Fragile X syndrome, and appointing an interim CEO following the former CEO’s termination in April 2026.
Anavex also disclosed that on May 20, 2026 it received a Nasdaq delinquency notification for not timely filing its Form 10-Q for the quarter ended March 31, 2026. The notice did not impact the current listing status, and the company has submitted a compliance plan and released preliminary second fiscal quarter results while working to complete outstanding periodic filings.
Anavex Life Sciences Corp. reported preliminary results for its fiscal second quarter ended March 31, 2026 and provided a business update centered on lead candidate ANAVEX®2‑73 (blarcamesine) for early Alzheimer’s disease, Rett syndrome and Fragile X syndrome, highlighting a disciplined, data‑driven regulatory strategy and FDA engagement.
Preliminary cash and cash equivalents were $127.4 million as of March 31, 2026, up from $102.6 million as of September 30, 2025, and the company states it expects this balance to fund operations into mid‑to‑late fiscal 2028. For the quarter, general and administrative expenses were $2.3 million versus $2.6 million a year earlier, and research and development expenses were $4.2 million versus $9.9 million, primarily reflecting completion of the ANAVEX® 3‑71 schizophrenia trial and lower clinical manufacturing activity. Net loss narrowed to $5.3 million, or $0.06 per share, from $11.2 million, or $0.13 per share, on a weighted‑average 92,675,753 shares versus 85,073,769.
All figures are preliminary and subject to completion of financial closing procedures. The company also cites risks related to regaining compliance with Nasdaq Listing Rule 5250(c)(1) after a delayed Form 10‑Q filing, alongside typical clinical, regulatory and financing uncertainties.
Anavex Life Sciences Corp. reports that on July 20, 2026 it submitted a Compliance Plan to the Listing Qualifications Department of The Nasdaq Stock Market to regain compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of all required periodic financial reports with the SEC.
The company previously received a deficiency notification letter on May 20, 2026 because it did not timely file its Form 10-Q for the quarter ended March 31, 2026. The notice has no immediate effect on the listing of its common stock, which continues to trade on The Nasdaq Global Select Market under the symbol AVXL. Nasdaq staff is reviewing the Compliance Plan and may grant an extension if it is accepted; if not, the company can request a hearing before an independent Hearings Panel.
Anavex Life Sciences Corp. scheduled its 2026 Annual Meeting of Stockholders for September 24, 2026. The Board of Directors set July 31, 2026 as the record date, determining which stockholders are entitled to receive notice of and vote at the meeting.
The company also set revised timing guidelines for stockholder proposals and director nominations because the 2026 meeting will occur more than 30 days after the prior year’s meeting. Proposals and nominations received on or before July 10, 2026 will be considered submitted within a reasonable time before proxy materials are printed and mailed.
Anavex Life Sciences Corp. reported that Nasdaq has notified the company it is out of compliance with Nasdaq Listing Rule 5250(c)(1) because it did not file its Form 10‑Q for the quarter ended March 31, 2026 on time. The company’s shares remain listed on the Nasdaq Global Select Market and continue trading under the symbol AVXL.
Anavex has until July 20, 2026 to submit a plan explaining how it will regain compliance. If Nasdaq accepts the plan, it may allow up to 180 days from the Form 10‑Q due date, through November 16, 2026, for Anavex to file and cure the delinquency. If Nasdaq does not accept the plan, the company could face a delisting process, though it would be able to appeal to a Nasdaq Hearings Panel. Anavex states it is working to complete the Form 10‑Q and submit its compliance plan.
Anavex Life Sciences Corp. reported the departure of its Chief Operating Officer, Felix Lauscher, effective May 11, 2026, as part of a broader reorganization of duties following the appointment of Dr. Terrie Kellmeyer as Interim Chief Executive Officer. Lauscher had served as COO since March 1, 2026.
Under his employment agreement, he received a prorated portion of his $264,000 annual base salary. He had been granted 50,000 stock options; 45,833 were forfeited upon departure, while 4,167 options that vested on March 31, 2026 remain exercisable until August 9, 2026 at $4.69 per share under the company’s Omnibus Incentive Plan. In connection with his departure, he was offered an additional two weeks of compensation at his base salary level in exchange for signing and not revoking a general release.
Anavex Life Sciences Corp. reported a leadership change and a pending filing delay. A special committee of independent directors ended the employment of President and Chief Executive Officer Christopher Missling, PhD, for Cause under his employment agreement and asked him to resign from the Board.
The Board appointed Terrie Kellmeyer, PhD, a veteran drug development executive and former Senior Vice President of Clinical Development at Anavex, as Interim Chief Executive Officer effective May 4, 2026. Her compensation includes a $500,000 base salary, a target bonus equal to 30% of salary, a $150,000 signing bonus, and 200,000 stock options. The company also expects to file a Form 12b-25 to extend the deadline for its Form 10-Q for the quarter ended March 31, 2026.
Anavex Life Sciences Corp. reported that it has withdrawn its application for EU marketing authorization of its lead drug candidate blarcamesine as an add-on therapy for adults with early Alzheimer’s disease. The application had been under review by the European Medicines Agency’s Committee for Medicinal Products for Human Use.
The withdrawal follows CHMP feedback indicating it would not be in a position to issue a positive opinion at this time. Anavex states it remains committed to the ongoing clinical development of blarcamesine and plans to gather additional data and conduct further analyses to address the points raised by the CHMP.
Anavex Life Sciences Corp. reported a governance update, announcing that its Board of Directors appointed Dr. Axel Paeger as a new director, effective February 23, 2026, to fill an existing vacancy. He will receive compensation consistent with other non-employee directors.
The Board determined that Dr. Paeger qualifies as an independent director under Securities Exchange Act rules and Nasdaq Capital Market listing standards. The company stated there are no special arrangements connected to his appointment and no related-party transactions requiring disclosure. A related press release dated February 23, 2026 was furnished as an exhibit.
Anavex Life Sciences Corp. reported fiscal 2026 first quarter results and provided a business update focused on its lead oral blarcamesine program in early Alzheimer’s disease and other central nervous system disorders.
For the quarter ended December 31, 2025, Anavex recorded a net loss of $5.7 million, improved from a net loss of $12.1 million a year earlier. Operating expenses fell to $6.8 million from $13.6 million, reflecting lower general and administrative as well as research and development spending. Net loss per share narrowed to $0.06 from $0.14, on a higher weighted average share count of 89,029,458 basic and diluted shares, up from 84,805,974.
The company ended December 31, 2025 with $131.7 million in cash and cash equivalents, up from $102.6 million as of September 30, 2025, and total stockholders’ equity of $126.6 million, compared with $94.9 million at September 30, 2025. Management reiterated its focus on advancing blarcamesine and other pipeline candidates and hosted a webcast to discuss the quarter.
Anavex Life Sciences Corp. (AVXL) reported that it has released its financial results for the fiscal year ended September 30, 2025. The company filed a Form 8-K to announce that these results are presented in a separate press release dated November 25, 2025, which is attached as Exhibit 99.1. The 8-K specifies that the results and the exhibit are being furnished under Item 2.02, meaning they are not treated as filed for certain liability purposes unless expressly incorporated into future reports.
Anavex Life Sciences reported a regulatory setback: the EMA’s Committee for Medicinal Products for Human Use (CHMP) issued a negative trend vote following the oral explanation for the Marketing Authorization Application (MAA) of blarcamesine.
The company plans to request a re-examination once the CHMP opinion is formally adopted and to provide additional biomarker data in line with feedback from CHMP, EMA, and the Alzheimer’s disease community. A press release with further details was provided as Exhibit 99.1.